Graviton Bioscience, led by CEO Sam Waksal, is partnering to advance ROCK2-based drug development targeting pulmonary arterial hypertension and other cardiovascular conditions. The move builds on Waksal’s earlier work on the ROCK2 target, which contributed to development of the chronic graft-versus-host disease medicine Rezurock. By expanding into additional indications, the collaboration aims to translate target validation into a broader cardiopulmonary pipeline. ROCK2 is part of signaling pathways implicated in vascular disease biology, and PH has been an area of sustained therapeutic development despite high unmet need. The announcement positions Graviton to leverage its platform and prior experience in disease biology while seeking partners who can support translation across preclinical and clinical stages. Details in the excerpt did not specify which indications or compounds are in scope for the partnership beyond PH and “other cardio conditions,” but it signals continued investment in ROCK2 as a mechanistic thesis.